Here is the reformatted text in markdown:

# PHARMA
## 2°4 August, 2025

The Dy. General Manager (Listing Dept.) The Manager — Listing Dept.,
BSE Limited, National Stock Exchange of India Ltd.,
Corporate Relationship Dept., Exchange Plaza, 5th Floor,
1st Floor, New Trading Ring, Plot No. C/1, G. Block,
P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E),
Mumbai - 400 001 Mumbai — 400 051
(BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM)

Dear Sir,

## Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The USFDA inspected our manufacturing facility at Vizag, Andhra Pradesh from 28 July 2025 to 01 August 2025.
The inspection has been concluded with Zero observations.

Please take the information on your records.
Thanking you,
Yours Sincerely

For TORRENT PHARMACEUTICALS LIMITED
M TRIVEDI

Chintan M. Trivedi

**COMPANY SECRETARY**

TORRENT PHARMACEUTICALS LIMITED
CIN: L24230GJ1972PLC002126
Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India.
Phone: +91 79 26599000, Fax: +91 79 26582100,
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com